Jefferies cuts Leidos stock price target on valuation reset

Jefferies cut its Leidos price target to $245 from $275 but maintained a Buy rating. It cited third-quarter organic growth accelerating 3 percentage points to 17% and margins expanding 310 basis points year over year to 19.8%, while noting longer-term margin goals in the mid-20% range and cash conversion targeted above 50%. Separately, the article reports mixed third-quarter 2026 results: adjusted EPS of $3.62 beat the $3.05 forecast, while revenue of $4.6 billion missed the $4.71 billion estimate; shares were down nearly 8% over the past week and 26% year to date.

Analysis

The investable signal is not the broker target cut; it is the gap between strong adjusted profit and weak consolidated revenue, alongside sharply conflicting descriptions of organic growth. Before assigning value to the growth/margin narrative, verify the 17% figure’s business scope and period against reported consolidated results. If growth is concentrated in a narrower defense-technology activity while Health and other programs contract, the market may be pricing mix and execution risk rather than rejecting the defense thesis outright. Buybacks can support per-share results but cannot repair underlying demand; using improved cash generation for acquisitions adds integration and valuation risk. In the next 1–3 months, the key catalysts are clarified segment growth, the VA contract outcome, and whether revenue estimates stabilize. Over 6–18 months, production ramps could improve the growth mix, but awards only matter when they convert into funded, executable work. The contrarian opportunity is that a defense-heavy portfolio may be discounted alongside weaker commercial-facing activity; the counterpoint is that attractive margin expansion is less durable if it is not accompanied by consolidated revenue growth. No valuation conclusion is justified by the conflicting source data. The thesis weakens if subsequent results show continued revenue/organic-growth deterioration, Health declines persist, or the VA issue creates a material program setback; it strengthens if reported growth broadens and cash conversion improves without acquisition dependence.

Key Decisions for Investors

• Do not trade off the $245 target in isolation. First reconcile the 17% organic-growth claim with the reported 0.6% consolidated figure by checking scope, period, and segment disclosures; treat the former as unverified for consolidated underwriting.
• Near term: stay neutral on LDOS rather than average down. Reassess after the next earnings update or a definitive VA contract development, focusing on consolidated revenue versus estimates, segment growth, and updated earnings revisions.
• Watch for a conditional long setup over 1–3 months only if revenue estimates stabilize and growth broadens beyond the strongest activities; use a defined-risk position and exit the thesis if reported organic growth continues to weaken or the VA issue materially impairs outlook.
• For a 6–18 month thesis, track funded awards converting to production and cash conversion before crediting defense-program growth or acquisition capacity. If cash generation rises while organic growth remains weak, treat buybacks as per-share support—not evidence of improving operating demand.